Focused On-demand Library for Deformed epidermal autoregulatory factor 1 homolog

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.







Alternative names:

Nuclear DEAF-1-related transcriptional regulator; Suppressin; Zinc finger MYND domain-containing protein 5

Alternative UPACC:

O75398; A8K1F8; A8K5R8; C7T5V5; O15152; O75399; O75510; O75511; O75512; O75513; Q9UET1


Deformed epidermal autoregulatory factor 1 homolog (DEAF-1), also known as Nuclear DEAF-1-related transcriptional regulator, Suppressin, and Zinc finger MYND domain-containing protein 5, plays a pivotal role in transcription regulation. It binds to specific DNA sequences, down-regulating transcription of certain genes, including its own. DEAF-1 is crucial for processes such as neural tube closure, skeletal patterning, and epithelial cell proliferation in the mammary gland. It also influences the expression of peripheral tissue antigens in pancreatic lymph nodes.

Therapeutic significance:

DEAF-1's involvement in Vulto-van Silfout-de Vries syndrome and Neurodevelopmental disorder with hypotonia suggests its potential as a therapeutic target. Understanding DEAF-1's role could open doors to novel treatments for these disorders, emphasizing the importance of further research into its functions and mechanisms.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.